Resource Type

Journal Article 596

Conference Videos 8

Year

2024 1

2023 34

2022 55

2021 64

2020 34

2019 54

2018 44

2017 46

2016 24

2015 32

2014 25

2013 32

2012 26

2011 23

2010 13

2009 29

2008 11

2007 19

2006 4

2005 2

open ︾

Keywords

fuel cell 13

immunotherapy 10

targeted therapy 8

solar cell 6

hematopoietic stem cell transplantation 5

hepatocellular carcinoma 5

hydrogen energy 5

lung cancer 5

stem cell 5

COVID-19 4

cancer 4

cell proliferation 4

control 4

microbial fuel cell 4

solid oxide fuel cell 4

High pressure 3

cancer immunotherapy 3

cancer therapy 3

chemotherapy 3

open ︾

Search scope:

排序： Display mode:

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation Article

Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang

Engineering 2019, Volume 5, Issue 1,   Pages 150-155 doi: 10.1016/j.eng.2018.12.006

Abstract: transplantation (allo-HSCT) for B cell acute lymphoblastic leukemia (B-ALL).Donor lymphoblastic infusion (DLI) is the main established approach to treat B-ALL with MRD after allo-HSCTAlthough donor-derived cluster of differentiation (CD)19-directed chimeric antigen receptor-modified (CAR) T83.33%) achieved MRD-negative remission, and one case was not responsive to the administration of CAR TDonor-derived CAR T cell infusions seem to be an effective and safe intervention for patients with MRD

Keywords： Donor-derived CD19-targeted T cell infusion     Hematopoietic stem cell transplantation     B cell acute lymphoblastic    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cellprecursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2There are other fusions or mutations that may serve as putative targets, but effective targeted therapycell therapy for B-ALL, and daratumumab and nelarabine for T-ALL.With the expanding therapeutic armamentarium, we should start focus on rational combinations of targeted

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell therapy    

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: In general, lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)Therefore, this information may be applied for early cancer detection, classification, novel targetedRecent clinical data have revealed that targeted therapy might be the second-line therapy as an alternativeTherefore, it is very important to select NSCLC patients with biomarkers to match targeted agents sothat we can further identify effectiveness of targeted therapy in the future.

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

Deubiquitinases as pivotal regulators of T cell functions

Xiao-Dong Yang, Shao-Cong Sun

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 451-462 doi: 10.1007/s11684-018-0651-y

Abstract:

T cells efficiently respond to foreign antigens to mediate immune responses against infections butDefect in T cell activation is associated with severe immune deficiencies, whereas aberrant T cell activationAn emerging mechanism that regulates T cell activation and tolerance is ubiquitination, a reversibleIt is now well recognized that DUBs are crucial regulators of T cell responses and serve as potentialThis review will discuss the recent progresses regarding the functions of DUBs in T cells.

Keywords： deubiquitinase     ubiquitination     T cell activation     T cell differentiation     T cell tolerance    

HTML PDF Collect

myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusionafter allogeneic hematopoietic stem cell transplantation

Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang

Frontiers of Medicine 2019, Volume 13, Issue 2,   Pages 238-249 doi: 10.1007/s11684-017-0599-3

Abstract: in patients with unsatisfactory response to minimal residual disease (MRD)-directed donor lymphocyte infusionDLI and could be a potential salvage treatment for these patients after allogeneic hematopoietic stem cell

Keywords： interferon-α     hematopoietic stem cell transplantation     minimal residual disease     donor lymphocyte infusion    

HTML PDF Collect

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 783-804 doi: 10.1007/s11684-021-0904-z

Abstract: Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematologicalIn this review, through a representative case study, we summarize the current experience of CAR T-cell, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell

Keywords： CAR T cells     hematological malignancies     review    

HTML PDF Collect

salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion

Frontiers of Medicine 2021, Volume 15, Issue 5,   Pages 728-739 doi: 10.1007/s11684-021-0833-x

Abstract: Relapse is the main problem after allogeneic hematopoietic stem cell transplantation (allo-HSCT).patients with relapsed/refractory acute leukemia (AL) post-chemotherapy plus modified donor lymphocyte infusion

Keywords： second hematopoietic stem cell transplantation     acute leukemia     relapse     chemotherapy     modified donorlymphocyte infusion    

HTML PDF Collect

Regulation of T cell immunity by cellular metabolism

Zhilin Hu, Qiang Zou, Bing Su

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 463-472 doi: 10.1007/s11684-018-0668-2

Abstract:

T cells are an important adaptive immune response arm that mediates cell-mediated immunity.T cell metabolism plays a central role in T cell activation, proliferation, differentiation, and effectorSpecific metabolic programs are tightly controlled to mediate T cell immune responses, and alterationsin T cell metabolism may result in many immunological disorders.in T cell metabolic programming during T cell homeostasis, differentiation, and function.

Keywords： T cell immunity     metabolic pathways     nutrient uptake     metabolic checkpoints    

HTML PDF Collect

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 69-82 doi: 10.1007/s11684-018-0677-1

Abstract:

Cytokine-activated T cells (CATs) can be easily expanded and are widely applied to cancer immunotherapyThe low-efficacy problem can be resolved using T cell antigen receptor-engineered CAT (TCR-CAT).TCR-CATs delivered significantly better activation and cytotoxicity than the equivalent TCR-engineered Tinterferon-g and granzyme B production and in vitro cancer cellTCR-CAT may be a very good alternative to the expensive TCR-T, which is considered an effective personalized

Keywords： cytokine-activated T cells     high-affinity T cell receptor     cancer immunotherapy     TCR-CAT    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: achieved complete remission after receiving the CD19 CAR-T cell therapy.cell therapy.Other than the CD19-targeted CAR-T, the novel target antigens, such as CD20, CD22, CD30, and CD37, whichTherefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy withthe toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAllogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemiaAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of TTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatmentThe overall response rate was 20% and 50% at 4 and 12 weeks after the infusion of C-CAR011, respectively, and the disease control rate was 60% at 12 weeks after infusion.

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 442-458 doi: 10.1007/s11684-021-0877-y

Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is one of the most dangerous hematological malignancies,More than 60% of T-ALL patients carry NOTCH1 gene mutations, leading to abnormal expression ofWe found that chidamide, an HDAC inhibitor, exerts an antitumor effect on T-ALL cell lines and primaryOur results highlight the effectiveness and safety of chidamide in the treatment of T-ALL patients, including

Keywords： T-cell acute lymphoblastic leukemia     HDAC inhibitor     chidamide     NOTCH1     MYC     ubiquitination    

HTML PDF Collect

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 815-826 doi: 10.1007/s11684-021-0891-0

Abstract: Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL)

Keywords： B-cell lymphoma     oral drug     targeted therapy     immunotherapy     COVID-19 pandemic    

HTML PDF Collect

Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:

Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao

Frontiers of Medicine 2015, Volume 9, Issue 4,   Pages 468-477 doi: 10.1007/s11684-015-0419-6

Abstract:

Mature T-cell lymphoid malignancies comprise a group of heterogeneous diseases that vary in clinicopathologicalBone marrow (BM) infiltration is more commonly present in mature T-cell lymphoid malignancies comparedthis study, clinical characteristics and prognostic factors were analyzed in 225 patients with mature T-cellThese included 29 cases of T-cell lymphoproliferative disorders (T-LPD, all with BM infiltration) and196 cases of T-/natural-killer-cell lymphoma (T/NKCL, 56 with BM infiltration and 140 without BM infiltration

Keywords： mature T-cell lymphoid malignancies     clonal T-cell population     bone marrow infiltration     prognostic factors    

HTML PDF Collect

Title Author Date Type Operation

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation

Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

Deubiquitinases as pivotal regulators of T cell functions

Xiao-Dong Yang, Shao-Cong Sun

Journal Article

myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusionafter allogeneic hematopoietic stem cell transplantation

Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang

Journal Article

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

Journal Article

salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion

Journal Article

Regulation of T cell immunity by cellular metabolism

Zhilin Hu, Qiang Zou, Bing Su

Journal Article

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

Journal Article

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Journal Article

Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:

Wen Xue,Yan Sheng,Xiangqin Weng,Yongmei Zhu,Yan Zhao,Pengpeng Xu,Xiaochun Fei,Xiaoyan Chen,Li Wang,Weili Zhao

Journal Article